Miltenyi Biotec Showcases Innovative Processes for Dendritic Cells Research in Immuno-oncology

Share Article

Through this webinar, which LabRoots will host December 12, those in attendance will better understand recent progress in immuno-oncology, and will review generation of monocyte-derived DCs.

Andrzej Dzionek, PhD R&D Manager: Dendritic Cell & B cells

Since their discovery, dendritic cells (DCs) have demonstrated a central role in the development of effective immune responses. Their unique ability to induce T cells responses to unknown antigens made them interesting research targets.

However, DCs are not an easy cell type to study due to their low frequency in the periphery, lack of univocal lineage markers and the fact that they cannot be expanded in vitro. Artificial systems have been developed to obtain DC-like cells in numbers compatible with their study. The standard is to generate DCs from peripheral blood progenitors. This method has been instrumental in developing not only our basic understanding of these cells but also in translational aspects.

Although the safety profile of DC approaches has been proven in several trials and objective responses were observed, their study has been hindered by technical difficulties, especially in clinical settings. Recently, individual DCs subtypes have been shown to respond differently to specific pathogen and tumor environments and that they may functionally complement each other to evoke an effective immune response.

The recent progress in immuno-oncology and the rapid development of new drugs, give potential to design novel and effective combination strategies to contrast the complex tumor settings. DCs may be an invaluable part of approaches aiming at targeting several checkpoints of anti-tumoral immune responses. In this webinar, which is sponsored by Miltenyi Biotec, the speaker will illustrate the CliniMACS Prodigy LP-14 System for generation of monocyte-derived DCs and the innovative LP-BDC for isolation and activation of primary DCs to investigate their clinical potential.

The speaker for this event will be Dr. Andrzej Dzionek, manager of research and development of Dendritic Cell & B cells at Miltenyi Biotec GmbH.

After completing his Masters of Science in biology, Dzionek went on to earned his doctorate in basic immunology from the University of Cologne. As an immunologist, he now serves as the head of R&D Reagents-Immunotherapy at Miltenyi Biotec GmbH. His group at Miltenyi Biotec GmbH develops assays, tools and reagents for research and clinical‐scale separation and analysis of dendritic cells, B‐cells and tumor reactive T-cells.

LabRoots will host the webinar December 12, 2017, beginning at 10 am PST. To read more about this event, learn of the continuing education credits that will be offered, or to register for free, click here.

About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotec’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Their more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In their commitment to the scientific community, Miltenyi Biotec also offers comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 1,500 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Sorenson
LabRoots, Inc.
+1 (619) 861-0590
Email >
Visit website